pT3-N90-beta-catenin Citations (16)
Originally described in: Distinct pathways of genomic progression to benign and malignant tumors of the liver.Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6. Epub 2007 Sep 4. PubMed Journal
Articles Citing pT3-N90-beta-catenin
| Articles |
|---|
| (Pro)renin receptor is crucial for Wnt/beta-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Shibayama Y, Fujimori T, Nguyen G, Hirose T, Totsune K, Ichihara A, Kitada K, Nakano D, Kobori H, Kohno M, Masaki T, Suzuki Y, Yachida S, Nishiyama A. Sci Rep. 2015 Mar 9;5:8854. doi: 10.1038/srep08854. PubMed |
| CFTR-beta-catenin interaction regulates mouse embryonic stem cell differentiation and embryonic development. Liu Z, Guo J, Wang Y, Weng Z, Huang B, Yu MK, Zhang X, Yuan P, Zhao H, Chan WY, Jiang X, Chan HC. Cell Death Differ. 2017 Jan;24(1):98-110. doi: 10.1038/cdd.2016.118. Epub 2016 Nov 11. PubMed |
| Pigment epithelium-derived factor attenuates myocardial fibrosis via inhibiting Endothelial-to-Mesenchymal Transition in rats with acute myocardial infarction. Zhang H, Hui H, Li Z, Pan J, Jiang X, Wei T, Cui H, Li L, Yuan X, Sun T, Liu Z, Zhang Z, Dong H. Sci Rep. 2017 Feb 7;7:41932. doi: 10.1038/srep41932. PubMed |
beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma.
Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A.
Cancer Discov. 2019 Jun 11. pii: 2159-8290.CD-19-0074. doi: 10.1158/2159-8290.CD-19-0074.
PubMed
Associated Plasmids |
| Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/beta-catenin-driven hepatocellular carcinoma. Toh TB, Lim JJ, Hooi L, Rashid MBMA, Chow EK. J Hepatol. 2020 Jan;72(1):104-118. doi: 10.1016/j.jhep.2019.08.035. Epub 2019 Sep 18. PubMed |
| Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Jiang T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Hepatology. 2021 Jul;74(1):233-247. doi: 10.1002/hep.31685. Epub 2021 Jul 12. PubMed |
| Inhibition of the Growth of Breast Cancer-Associated Brain Tumors by the Osteocyte-Derived Conditioned Medium. Sano T, Sun X, Feng Y, Liu S, Hase M, Fan Y, Zha R, Wu D, Aryal UK, Li BY, Sudo A, Yokota H. Cancers (Basel). 2021 Mar 3;13(5). pii: cancers13051061. doi: 10.3390/cancers13051061. PubMed |
| Preventing tumor progression to the bone by induced tumor-suppressing MSCs. Sun X, Li K, Zha R, Liu S, Fan Y, Wu D, Hase M, Aryal UK, Lin CC, Li BY, Yokota H. Theranostics. 2021 Mar 5;11(11):5143-5159. doi: 10.7150/thno.58779. eCollection 2021. PubMed |
| Generation of the tumor-suppressive secretome from tumor cells. Liu S, Sun X, Li K, Zha R, Feng Y, Sano T, Dong C, Liu Y, Aryal UK, Sudo A, Li BY, Yokota H. Theranostics. 2021 Jul 25;11(17):8517-8534. doi: 10.7150/thno.61006. eCollection 2021. PubMed |
| Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFbeta/FN1/CD44 signaling. Sun X, Li K, Hase M, Zha R, Feng Y, Li BY, Yokota H. Theranostics. 2022 Jan 1;12(2):929-943. doi: 10.7150/thno.66148. eCollection 2022. PubMed |
| A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Wei Y, Wang Y, Liu N, Qi R, Xu Y, Li K, Feng Y, Shi B. Front Pharmacol. 2022 Jan 18;12:820446. doi: 10.3389/fphar.2021.820446. eCollection 2021. PubMed |
| Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. PubMed |
| Generation of the Chondroprotective Proteomes by Activating PI3K and TNFalpha Signaling. Sun X, Li KX, Figueiredo ML, Lin CC, Li BY, Yokota H. Cancers (Basel). 2022 Jun 21;14(13):3039. doi: 10.3390/cancers14133039. PubMed |
| Immunoediting instructs tumor metabolic reprogramming to support immune evasion. Tsai CH, Chuang YM, Li X, Yu YR, Tzeng SF, Teoh ST, Lindblad KE, Di Matteo M, Cheng WC, Hsueh PC, Kao KC, Imrichova H, Duan L, Gallart-Ayala H, Hsiao PW, Mazzone M, Ivanesevic J, Liu X, de Visser KE, Lujambio A, Lunt SY, Kaech SM, Ho PC. Cell Metab. 2023 Jan 3;35(1):118-133.e7. doi: 10.1016/j.cmet.2022.12.003. PubMed |
| CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Zhu GQ, Tang Z, Huang R, Qu WF, Fang Y, Yang R, Tao CY, Gao J, Wu XL, Sun HX, Zhou YF, Song SS, Ding ZB, Dai Z, Zhou J, Ye D, Wu DJ, Liu WR, Fan J, Shi YH. Cell Discov. 2023 Mar 6;9(1):25. doi: 10.1038/s41421-023-00529-z. PubMed |
| MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. Zhu C, Soto-Feliciano YM, Morris JP, Huang CH, Koche RP, Ho YJ, Banito A, Chen CW, Shroff A, Tian S, Livshits G, Chen CC, Fennell M, Armstrong SA, Allis CD, Tschaharganeh DF, Lowe SW. Elife. 2023 Jun 1;12:e80854. doi: 10.7554/eLife.80854. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.